Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860807 | 1.00 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| SCHEMBL939043 | 1.00 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| SCHEMBL4073511 | 1.00 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| SCHEMBL8058962 | 1.00 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| SCHEMBL487425 | 1.00 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| SCHEMBL6027457 | 0.98 | DPP4 (0.54) | DPP4LMNAMAPK1CYP2D6SRC | |
| Hydrochloric Acid SCHEMBL5860803 | 0.98 | DPP4 (0.54) | DPP4LMNAMAPK1CYP2D6SRC | |
| Hydrochloric Acid SCHEMBL8073692 | 0.98 | DPP4 (0.54) | DPP4LMNAMAPK1CYP2D6SRC | |
| Hydrochloric Acid SCHEMBL3184809 | 0.98 | DPP4 (0.54) | DPP4LMNAMAPK1CYP2D6SRC | |
| Cadaverine Tartrate SCHEMBL30110790 | 0.91 | DPP4 (0.64) | DPP4LMNAMAPK1CYP2D6SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406371-B | Process for producing 3-phenylisoserine derivative | 东丽精细化工株式会社 | 2020-07-17 | — | — | CN | claimed |
| EP-3266761-B1 | 3-PHENYLISOSERINE DERIVATIVE PRODUCTION METHOD | TORAY FINECHEMICALS CO LTD (JP) | 2020-05-06 | — | — | EP | claimed |
| US-10087139-B2 | 3-Phenylisoserine derivative production method | TORAY FINE CHEMICALS CO., LTD. (JP) | 2018-10-02 | — | — | US | claimed |
| US-20180237384-A1 | 3-PHENYLISOSERINE DERIVATIVE PRODUCTION METHOD | TORAY FINE CHEMICALS CO., LTD. (JP) | 2018-08-23 | — | — | US | claimed |
| EP-3266761-A1 | 3-PHENYLISOSERINE DERIVATIVE PRODUCTION METHOD | Toray Fine Chemicals Co., Ltd. (JP) | 2018-01-10 | — | — | EP | claimed |
| CN-107406371-A | The manufacture method of 3 phenylisoserine derivatives | 东丽精细化工株式会社 | 2017-11-28 | — | — | CN | claimed |
| JP-4664903-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| WO-2010024762-A1 | PREPARATION OF β-PHENYL-ISOSERINE DERIVATIVES | ORGANOCLICK AKTIEBOLAG (SE) | 2010-03-04 | — | — | WO | claimed |
| EP-1961735-B1 | Process for the preparation of (2r,3s)-3-phenylisoserine methyl ester acetate salt | INDENA SPA (IT) | 2009-11-18 | — | — | EP | claimed |
| EP-1615902-B1 | METHOD FOR PRODUCTION OF 4,10 BETA-DIACETOXY-2 ALPHA-BENZOYLOXY-5 BETA,20-EPOXY-1,13 ALPHA-DIHYDROXY-9-OXO-19-NORCYCLOPROPA[G]TAX-11-ENE | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | EP | claimed |
| EP-0599973-A1 | PROCESS FOR THE PREPARATION OF BETA-PHENYLISOSERINE DERIVATIVES AND USE THEREOF | Aventis Pharma S.A. (FR) | 1994-06-08 | — | — | EP | claimed |
| WO-1994007847-A1 | METHOD FOR THE STEREOSELECTIVE PREPARATION OF A DERIVATIVE OF β-PHENYLISOSERINE AND ITS USE IN THE PREPARATION OF TAXANE DERIVATIVES | RHONE-POULENC RORER S.A. (FR) | 1994-04-14 | — | — | WO | claimed |
| WO-1993017997-A1 | METHOD FOR PREPARING β-PHENYLISOSERINE AND ANALOGUES THEREOF | RHONE-POULENC RORER S.A. (FR) | 1993-09-16 | — | — | WO | claimed |
| US-RE34277-E | Process for preparing taxol | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1993-06-08 | — | — | US | claimed |
| WO-1993004038-A1 | PROCESS FOR THE PREPARATION OF BETA-PHENYLISOSERINE DERIVATIVES AND USE THEREOF | RHONE-POULENC RORER S.A. (FR) | 1993-03-04 | — | — | WO | claimed |
| WO-1993003838-A1 | CHIRAL CATALYSTS, CATALYTIC OXIDATION AND DISPROPORTIONATION REACTIONS, AND METHODS OF PRODUCING EPOXYCHROMANS AND TAXOL | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1993-03-04 | — | — | WO | claimed |
| EP-0528729-A1 | Process for the preparation of beta-phenylisoserine derivatives and their utilisation | Aventis Pharma S.A. (FR) | 1993-02-24 | — | — | EP | claimed |
| EP-0515540-A1 | DERIVATIVE OF BETA-PHENYLISOSERINE, PREPARATION AND UTILISATION THEREOF. | RHONE POULENC RORER SA (FR) | 1992-12-02 | — | — | EP | claimed |
| WO-1991013053-A1 | DERIVATIVE OF β-PHENYLISOSERINE, PREPARATION AND UTILISATION THEREOF | RHONE-POULENC RORER S.A. (FR) | 1991-09-05 | — | — | WO | claimed |
| US-4924011-A | CONDENSATION, ESTERIFICATION; ANTITUMOR AND ANITLEUKEMIA AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1990-05-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237384-A1 | 3-PHENYLISOSERINE DERIVATIVE PRODUCTION METHOD | SPTSSB, PIM3, TST | DPP4 1591/4885LMNA 3094/4885MAPK1 1131/4885 |
| US-10087139-B2 | 3-Phenylisoserine derivative production method | SPTSSB, PIM3, TST | DPP4 1591/4885LMNA 3094/4885MAPK1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.